SC dismisses PIL against Ranbaxy
It is a welcome relief for embattled pharma major Ranbaxy. On Tuesday
(June 25), the Supreme Court dismissed a public interest litigation
(PIL) seeking a probe against Ranbaxy Laboratories for allegedly
manufacturing and selling substandard medicines in India.
E Kumar Sharma- New Delhi,
- Updated Jun 25, 2013 11:57 PM IST
It is a welcome relief for embattled pharma major Ranbaxy. On Tuesday (June 25), the Supreme Court dismissed a public interest litigation (PIL) seeking a probe against Ranbaxy Laboratories for allegedly manufacturing and selling substandard medicines in India.
"We are happy with the judgment of the honourable Supreme Court," said a company spokesperson. "At Ranbaxy, we are committed to patient safety and ethical business practices and we will continue to offer high quality drug products to all of our customers in India and worldwide."
Analysts however do not see this as either a positive or a negative development, since the PIL, in the view of the court, was not backed by evidence to support its arguments.
Published on: Jun 25, 2013 12:16 PM IST